Relmada Therapeutics (RLMD) to Release Quarterly Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) will issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter.

Relmada Therapeutics (NASDAQ:RLMD) last announced its earnings results on Wednesday, August 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24. During the same period last year, the business posted ($0.84) earnings per share. On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Relmada Therapeutics Price Performance

NASDAQ:RLMD traded down $0.11 during trading hours on Tuesday, reaching $3.31. 54,589 shares of the stock were exchanged, compared to its average volume of 181,769. The stock has a market cap of $99.86 million, a PE ratio of -1.12 and a beta of 0.41. Relmada Therapeutics has a twelve month low of $1.88 and a twelve month high of $7.22. The firm has a 50 day moving average of $3.26 and a 200 day moving average of $3.30.

Insider Buying and Selling

In other news, CFO Maged Shenouda bought 24,120 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was acquired at an average cost of $2.95 per share, with a total value of $71,154.00. Following the completion of the purchase, the chief financial officer now owns 88,335 shares of the company’s stock, valued at $260,588.25. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Maged Shenouda purchased 24,120 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $71,154.00. Following the completion of the purchase, the chief financial officer now directly owns 88,335 shares in the company, valued at $260,588.25. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sergio Traversa acquired 55,579 shares of the stock in a transaction dated Monday, September 9th. The shares were purchased at an average price of $2.71 per share, for a total transaction of $150,619.09. Following the completion of the purchase, the chief executive officer now directly owns 299,603 shares in the company, valued at $811,924.13. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 152,300 shares of company stock worth $429,655. Corporate insiders own 18.00% of the company’s stock.

Analysts Set New Price Targets

Separately, Jefferies Financial Group upgraded shares of Relmada Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the stock from $3.50 to $13.00 in a report on Tuesday, September 17th.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.